Ensifentrine
A dual inhibitor of phosphodiesterase 3 and 4
| Ensifentrine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ensifentrine is a novel bronchodilator and anti-inflammatory agent that is being investigated for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), which are enzymes involved in the regulation of intracellular levels of cyclic adenosine monophosphate (cAMP).
Mechanism of Action[edit | edit source]
Ensifentrine works by inhibiting the activity of PDE3 and PDE4, leading to an increase in intracellular cAMP levels. This results in relaxation of the airway smooth muscle, providing a bronchodilatory effect, and also reduces inflammation in the airways. The dual inhibition of PDE3 and PDE4 is thought to provide a synergistic effect, enhancing both bronchodilation and anti-inflammatory actions.
Clinical Development[edit | edit source]
Ensifentrine is currently undergoing clinical trials to evaluate its efficacy and safety in patients with COPD. Early studies have shown that it can improve lung function and reduce symptoms in patients with moderate to severe COPD. The drug is administered via inhalation, which allows for direct delivery to the lungs and minimizes systemic exposure.
Potential Benefits[edit | edit source]
The dual action of ensifentrine as both a bronchodilator and anti-inflammatory agent makes it a promising candidate for the treatment of COPD, a condition characterized by chronic inflammation and airflow limitation. By targeting both aspects of the disease, ensifentrine may offer improved symptom control and quality of life for patients.
Side Effects[edit | edit source]
As with any medication, ensifentrine may cause side effects. Common side effects observed in clinical trials include headache, cough, and throat irritation. The safety profile of ensifentrine is still being evaluated in ongoing studies.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
